Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Extensive stage small cell lung cancer (ES-SCLC), first-line treatment, in combination with a platinum-based chemotherapy and etoposide
Last updated:
February 11, 2022
Entuzity KwikPen (human insulin)
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
February 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Chronic fibrosing interstitial lung diseases
Last updated:
February 5, 2022
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Spinal Muscular Atrophy
Last updated:
January 19, 2022
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, first-line treatment (in combination with ipilimumab and 2 cycles of platinum-based chemotherapy)
Last updated:
January 18, 2022
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Unresectable malignant pleural mesothelioma (MPM) in adult patients who have not received prior systemic therapy for MPM (in combination with ipilimumab)
Last updated:
January 18, 2022
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer and Deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM, monotherapy for the treatment of adult patients with mCRPC who have progressed following prior treatment with a NHA
Last updated:
January 17, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Carcinoma of the colon or rectum, metastatic, first-line treatment in combination with fluoropyrimidine based chemotherapy or patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen
Last updated:
January 14, 2022
Status:
Concluded with an LOI
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated:
December 20, 2021
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, previously untreated with an ALK inhibitor, in adult patients
Last updated:
December 16, 2021